Categories: BioTechInformationMedtechPlatform
Helicore Biopharma, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics to address obesity and related metabolic conditions. The company is advancing a portfolio of next-generation treatments with a novel approach to glucose-dependent insulinotropic peptide (GIP) antagonism. Helicore’s proprietary platform leverages monoclonal antibodies that bind circulating GIP ligand, designed to improve the efficacy, dosing, and tolerability of anti-obesity therapies. Helicore is rapidly advancing a differentiated portfolio that may deliver superior treatment outcomes through enhanced efficacy, tolerability and convenient dosing regimens. Following the close of a $65M Series A financing in January 2024, Helicore is well-positioned to drive progress in this critical area of unmet need. For more information, visit www.helicore.com.
Investors 1
Mentions in press and media 2
Reviews 0
